Literature DB >> 22211246

Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells.

Syu-Ichi Kanno1, Naoyuki Maeda, Ayako Tomizawa, Shin Yomogida, Tadashi Katoh, Masaaki Ishikawa.   

Abstract

Spiruchostatin B (SP-B) is a potent histone deacetylase (HDAC) inhibitor that has potential for the chemotherapy of leukemia. The aim of this study was to study the susceptibility of human leukemia cell lines to SP-B. We found that NALM-6 human B cell leukemia cells are the most susceptible to SP-B. There was a low correlation between the expression of HDAC1 mRNA and HDI susceptibility of leukemia cells. NALM-6 has higher endogenous p21waf1/cip1 mRNA expression than other leukemia cells. SP-B-induced cytotoxicity was mediated by induction of histone acetylation via inhibition of HDACs, and this effect of SP-B was associated with apoptosis, which was mediated by caspase activation in NALM-6 cells. SP-B time-dependently increased the size of the sub-G1 (apoptotic) peak, and this effect correlated with SP-B induction of cellular apoptotic features such as changes in nuclear morphology. SP-B significantly increased p21waf1/cip1 expression prior to induction of apoptosis. In conclusion, NALM-6 cells, which have a higher expression of p21waf1/cip1 mRNA than other leukemia cell lines, were susceptible to SP-B-induced cytotoxicity that resulted in induction of apoptosis. Our findings may be useful when establishing a therapeutic strategy based on SP-B.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22211246     DOI: 10.3892/ijo.2011.1323

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.

Authors:  Matthew C Stubbs; Wonil Kim; Megan Bariteau; Tina Davis; Sridhar Vempati; Janna Minehart; Matthew Witkin; Jun Qi; Andrei V Krivtsov; James E Bradner; Andrew L Kung; Scott A Armstrong
Journal:  Clin Cancer Res       Date:  2015-02-16       Impact factor: 12.531

2.  Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines.

Authors:  Syu-Ichi Kanno; Katsuyuki Itoh; Naoto Suzuki; Ayako Tomizawa; Shin Yomogida; Masaaki Ishikawa
Journal:  Mol Clin Oncol       Date:  2012-06-27

3.  Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.

Authors:  Syu-Ichi Kanno; Naoyuki Maeda; Ayako Tomizawa; Shin Yomogida; Tadashi Katoh; Masaaki Ishikawa
Journal:  Int J Oncol       Date:  2012-06-06       Impact factor: 5.650

4.  The Role of HDACs as Leukemia Therapy Targets using HDI.

Authors:  Ahmad Ahmadzadeh; Elahe Khodadi; Mohammad Shahjahani; Jessika Bertacchini; Tina Vosoughi; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-10-01

5.  Overexpression of Programmed Cell Death 1 Prevents Doxorubicin-Induced Apoptosis Through Autophagy Induction in H9c2 Cardiomyocytes.

Authors:  Syu-Ichi Kanno; Akiyoshi Hara
Journal:  Cardiovasc Toxicol       Date:  2022-02-21       Impact factor: 3.231

6.  Induction of apoptosis by a potent caffeic acid derivative, caffeic acid undecyl ester, is mediated by mitochondrial damage in NALM-6 human B cell leukemia cells.

Authors:  Ayako Tomizawa; Syu-ichi Kanno; Yuu Osanai; Akane Goto; Chizuru Sato; Shin Yomogida; Masaaki Ishikawa
Journal:  Oncol Rep       Date:  2012-12-03       Impact factor: 3.906

7.  Cytotoxic effects of caffeic acid undecyl ester are involved in the inhibition of telomerase activity in NALM-6 human B-cell leukemia cells.

Authors:  Ayako Tomizawa; Syu-Ichi Kanno; Yuu Osanai; Shin Yomogida; Masaaki Ishikawa
Journal:  Oncol Lett       Date:  2013-07-23       Impact factor: 2.967

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.